Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 30 results found. Search for [ non-hospitalised patients ]

Results 1 to 21 of 30
Reuters
October 28, 2020
A non-peer-reviewed study of more than 84,000 people, led by Adam Hampshire, a doctor at Imperial College London, found that in some severe cases, coronavirus infection is linked to substantial cognitive deficits for months


BusinessToday.In
October 8, 2020
Donald Trump, who was admitted at Walter Reed National Military Medical centre on Friday, had received \"a single 8-gram dose\" of Regeneron's monoclonal antibody cocktail


PTI
September 5, 2020
The Indian Council of Medical Research (ICMR) on Friday issued a new advisory on COVID-19 testing strategy, allowing 'testing on demand' for individuals but left it to the states to modify the approach as per their discretion


PB Jayakumar
September 3, 2020
WHO's recommendation is based on three new studies, plus four other earlier trials, all involving a drug from the family of corticosteroids


PTI
August 31, 2020
The government should also provide data separately on the number of suspected COVID-19 cases and the cases being reported in urban and rural areas


Aprajita Sharma
August 10, 2020
The policy also provides 100 per cent coverage of medical expenses, and covers the typical non-payable expenses like personal protective equipment kit, gloves, oxygen masks, conveyance charges and more, under the safeguard benefit


PTI
August 4, 2020
On July 20, 2020, the company received approval from the Drug Controller General of India (DCGI) to manufacture and market remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19


E Kumar Sharma
July 23, 2020
Most complain of unusually long fatigue after a corona illness as opposed to a common cold or common flu where you are up and about in a few days


PTI
July 15, 2020
Covifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitalised with severe symptoms of the disease


BusinessToday.In
July 13, 2020
Last month, Cipla introduced Remdesivir under the brand name 'CIPREMI' after receiving approval from DCGI for \"restricted emergency use\" on adult and paediatric patients hospitalised with suspected or laboratory-confirmed COVID-19 infection


Reuters
July 5, 2020
The UN agency said that the decision, taken on the recommendation of the trial's international steering committee, does not affect other studies where the drugs are used for non-hospitalised patients or as prophylaxis


PB Jayakumar
June 24, 2020
Remdesivir, allowed for emergency use in COVID-19 patients from May 1, is currently given as an injection and can be used only in hospitals


BusinessToday.In
June 22, 2020
India's Drug Regulator gave permission to Hetero and Cipla to manufacture and market antiviral drug remdesivir for \"restricted emergency use\" on hospitalised COVID-19 patients


Vivek Dubey
New Delhi, June 21, 2020
Gilead Sciences, in May, had extended a voluntary non-exclusive license to Cipla to manufacture and market Cipla's generic version of remedisvir called CIPREMI


Associated Press
June 13, 2020
Four companies -- Hetero, Jubilant Life Sciences, Cipla and Mylan NV -- with which the original drug maker, Gilead Sciences Inc, have entered into non-exclusive licensing agreements are still awaiting nod from the DCGI for manufacturing and selling of remdesivir in India


BusinessToday.In
New Delhi, June 3, 2020
The experimental treatment, LY-CoV555, has been developed through collaboration with privately held AbCellera Biologics, which Lilly partnered with in March


PTI
June 2, 2020
The drug has been allowed for restricted emergency use for treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalised with severe symptoms, subject to several safeguards, the source said


PTI
May 30, 2020
Gilead Sciences Inc have entered into non-exclusive licensing agreements with pharma firms including three domestic majors Cipla, Jubilant Life Sciences and Hetero for manufacture and distribution of remdesivir


E Kumar Sharma
New Delhi, May 27, 2020
Coronavirus crisis: WHO is currently assessing the use of hydroxychloroquine on COVID-19 patients within the Solidarity Trial. The hydroxychloroquine arm of the trial has been paused as a precaution while the safety data is being reviewed.


PTI
May 13, 2020
According to the order, the Ayushman Bharat-Pradhan Mantri Jan Arogya Yojna beneficiaries being hospitalised in AIIMS and all centres will continue to get requisite benefits under the scheme as before


PAGES 1 OF 2  12